NEW YORK, Oct. 21-Lion Bioscience expects its revenues for the year to fall by as much as 25 percent from last year's totals, the company said today. In a statement released this morning, CEO Friedrich von Bohlen blamed non-cash write-offs, a shift from in-house drug discovery, and the general malaise in the life sciences industry for the shortfall.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.